z-logo
open-access-imgOpen Access
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Author(s) -
Lindsey R. Baden,
Hana M. El Sahly,
Brandon Essink,
Karen L. Kotloff,
Sharon E. Frey,
Rick Novak,
David Diemert,
Stephen A. Spector,
Nadine Rouphael,
C. Buddy Creech,
John McGettigan,
Shishir Khetan,
Nathan Segall,
Joel Solis,
Adam Brosz,
Carlos Fierro,
Howard Schwartz,
Kathleen M. Neuzil,
Lawrence Corey,
Peter B. Gilbert,
Holly Janes,
Dean Follmann,
Mary Marovich,
John R. Mascola,
Laura Polakowski,
Julie E. Ledgerwood,
Barney S. Graham,
Hamilton Bennett,
Rolando Pajón,
Conor Knightly,
Brett Leav,
Weiping Deng,
Haiyu Zhou,
Shu Han,
Melanie Ivarsson,
Jacqueline M. Miller,
Tal Zaks
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa2035389
Subject(s) - virology , covid-19 , medicine , messenger rna , biology , gene , genetics , infectious disease (medical specialty) , disease
Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom